Cell replacement therapy is a promising treatment for irreversible retinal cell death in diverse diseases, such as agerelated macular degeneration (AMD), Stargardt's disease, retinitis pigmentosa (RP) and glaucoma. These diseases are all characterized by the degeneration of one or two retinal cell types that cannot regenerate spontaneously in humans. Aberrant retinal pigment epithelial (RPE) cells can be observed through optical coherence tomography (OCT) in AMD patients. In RP patients, the morphological and functional abnormalities of RPE and photoreceptor layers are caused by a genetic abnormality. Stargardt's disease or juvenile macular degeneration, which is characterized by the loss of the RPE and photoreceptors in the macular area, causes central vision loss at an early age. Loss of retinal ganglion cells (RGCs) can be observed in patients with glaucoma. Once the retinal cell degeneration is triggered, no treatments can reverse it. Transplantation-based approaches have been proposed as a universal therapy to target patients with various concomitant diseases. Both the replacement of dead cells and neuroprotection are strategies used to rescue visual function in animal models of retinal degeneration. Diverse retinal cell types derived from pluripotent stem cells, including RPE cells, photoreceptors, RGCs and even retinal organoids with a layered structure, provide unlimited cell sources for transplantation. In addition, mesenchymal stem cells (MSCs) are multifunctional and protect degenerating retinal cells. The aim of this review is to summarize current findings from preclinical and clinical studies. We begin with a brief introduction to retinal degenerative diseases and cell death in diverse diseases, followed by methods for retinal cell generation. Preclinical and clinical studies are discussed, and future concerns about efficacy, safety and immunorejection are also addressed.
Introduction
The eye is a pivotal organ for human life. Humans capture most of the information regarding their environment through their eyes. Thus, the eye is also called the window of the brain. In addition, the economic burden of visual impairment on patients' families, the national healthcare system and society is considerable. As projected by the plays an indispensable role in the visual signaling process. Visual signaling starts in photoreceptor cells which express photosensitive proteins mostly in the outer segments. In the human retina, two types of photoreceptor cells, rods and cones, are responsible for dim light vision and daylight vision (including color), respectively. Rods are located mainly in the peripheral retina, and cones are concentrated in a small portion of the retina, the macula, which provides high-resolution central vision. Bipolar cells receive visual signals from photoreceptor cells and transmit these signals to RGCs coordinated by horizontal and amacrine cells. Ultimately, all the signals are gathered in the optic nerve and transmitted to the brain. Both cell degeneration and synaptic disruption can cause permanent visual impairment or even blindness.
Retinal pigment epithelium (RPE) cells form a monolayer underneath the outer segments of the photoreceptors, constituting the outer bloodretinal barrier. In the visual system, RPE cells play diverse roles, including absorption of scattered light, regulation of nutrients and solutes, secretion of growth factors, regulation of the retinal cycle and phagocytosis of the photoreceptor outer segment (POS). The pigment in RPE cells increases visual quality by forming a dark chamber, which aids in the absorption of stray light. As a transporting epithelium, the RPE possesses structural properties for ion transport. Furthermore, the RPE is polarized, with different compartments and membrane proteins between the apical and basolateral sides. On the apical side, the RPE extends long microvilli and expresses α v β 5 integrin, which aids in the phagocytosis of constantly shed POS discs. In addition, the RPE participates in retinal reisomerization. During the transduction of light energy into electrical impulses, 11-cis-retinal first binds to opsin and then is released from opsin as all-trans-retinal in photoreceptors. All-trans-retinal is transferred into the RPE for regeneration into 11-cis-retinal by a series of enzymes, including RPE65. The apical and basolateral sides of the RPE secrete different growth factors. For example, pigment epithelium-derived factor (PEDF) is secreted from the apical side, whereas vascular endothelial growth factor (VEGF) is secreted from the basolateral side (Strauss, 2005) . Since RPE cells are incapable of regeneration after birth, death or dysfunction of these cells can cause permanent vision loss.
Bruch's membrane (BM), which lies between the choriocapillaris and outer RPE basal membrane, is composed of a central elastin layer and two collagenous layers. The three primary functions of BM include regulating molecular exchange between the choroid and RPE; providing physical support for RPE cell adhesion, migration and perhaps differentiation; and forming a division barrier for cell migration. Changes in BM, such as the appearance of basal laminar deposits and membranous debris, lipid accumulation, thickness changes and drusen development, start at age 30 (Booij et al., 2010) . These continuous changes, which are considered a part of aging, may also participate in the pathogenesis of age-related macular degeneration (AMD). However, the boundary between normal and pathogenic aging is unclear. The morphology and dynamic changes in BM have been previously reviewed (Booij et al., 2010) .
Underneath the BM is the choroid, which can be divided into the choriocapillaris, Sattler's layer, Haller's layer, and the suprachoroidea. The choriocapillaris is a relatively dense vessel bed that lies adjacent to the BM. Its main functions are the transportation of oxygen and nutrients to the RPE and photoreceptor cells and removal of the debris from BM via systemic circulation. In the choriocapillaris endothelial cells, molecules involved in innate immunity are constitutively expressed, such as intercellular adhesion molecule-1 (ICAM-1) and MHC class I antigens (Goverdhan et al., 2005; McLeod et al., 1995; Mullins et al., 2006) . Previous studies have reported that choriocapillaris loss occurs in early-and intermediate-stage AMD (Borrelli et al., 2017; Seddon et al., 2016) . The structural changes and pathophysiology of AMD have been extensively discussed (Klein et al., 2005; Sarks et al., 1999; Whitmore et al., 2015) .
Retinal degenerative diseases are characterized by retinal cell loss, such as RPE and/or photoreceptor cell loss in AMD and retinitis pigmentosa (RP), and RGC death in glaucoma (Fig. 1) . Typically, visual impairment caused by degenerating retinal cells is irreversible because retinal cells lack self-repair capability. Improvement of visual acuity in patients with macular degeneration after transplantation of autologous RPE from the peripheral retina into the submacular space provides proof-of-principle evidence that RPE transplantation is a viable future therapeutic modality for retinal degenerative diseases (Binder et al., 2002 (Binder et al., , 2004 van Meurs et al., 2004) . However, the development of cell replacement therapy is bottlenecked by a shortage of cell sources and by genetic defects in patients' autologous cells.
Stem cells, which are characterized by unlimited proliferation and the potential to generate all kinds of cells, are a promising cell source for cell replacement therapy. The approaches for derivation of retinal cells from human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) have been explored after the establishment of stem cell culture, and successful results has been achieved by many groups (Idelson et al., 2009; Jin et al., 2009; Jin and Takahashi, 2012; Klimanskaya et al., 2004; Lund et al., 2006) . Thus, stem cell-derived retinal cells provide a near-unlimited cell source for cell transplantation. In addition, due to their neuroprotective, immunomodulatory and antioxidant properties, mesenchymal stem cells (MSCs) are promising for the treatment of neurodegenerative diseases. The protective effects of MSCs on the degeneration of RGCs have been demonstrated in an animal model of glaucoma ; the underlying mechanism may be related to retinal reactive gliosis (Tassoni et al., 2015) .
Relative to other organs of the human body, the eye can be easily accessed for surgical intervention with limited trauma due to its unique structure and anatomical character. The eye is a relatively independent organ, and intraocular cell transplantation is unlikely to affect other organs. Moreover, regular ophthalmic examinations are capable of follow-up tracing cell graft noninvasively and monitoring of blood vessel changes and therapeutic effects in vivo.
The main purpose of this review is to update knowledge of cell replacement therapy in preclinical and clinical studies targeting retinal degeneration. We begin this review by discussing the pathogenesis of retinal degenerative diseases, but do not address this topic in detail because it has been discussed at length in other reviews (De Jong, 2006; Gupta and Yücel, 2007; Hartong et al., 2006) . Next, we discuss the differentiation of retinal cells and retinal tissue from hESCs and iPSCs and then explore the results of preclinical studies. Finally, completed and ongoing clinical trials are presented, and future directions and major concerns in promoting stem cell-based therapy for retinal degenerative diseases are addressed.
Retinal degenerative diseases requiring cell replacement therapy

Age-related macular degeneration
AMD is the leading cause of blindness in the elderly population, with individuals over 70 years of age at especially high risk; this disease is predicted to affect almost 200 million people by 2020 . With the aging of the global population, an increased need for healthcare and the associated economic burden result in rising costs for the elderly population. At the early stage, the key sign of AMD is the appearance of drusen, which are visible with a diameter of > 25 μm (Hageman et al., 2001; Sarks et al., 1999) . Drusen are composed of lipids, proteins, small RNAs and lipofuscin granules (Crabb et al., 2002) . Some of these components can induce inflammasome activation, which may exacerbate the degeneration of retinal cells. The late stage of AMD can be categorized into two forms, neovascular wet AMD and non-neovascular dry AMD, also called geographic atrophy. In some of these patients, choriocapillaris changes can be detected (Curcio et al., 2013; Kim et al., 2013) , and choriocapillaris endothelial cell death results in ghost vessels (Whitmore et al., 2015) . A possible causative factor of choriocapillaris endothelial cell death is the accumulation of the membrane attack complex (MAC) (Mullins et al., 2014) . These studies were extended by Mullins et al. who found that macula with more ghost vessels had significantly more sub-RPE deposits than eyes with fewer ghost vessels (Mullins et al., 2011) . However, whether choriocapillaris dropout is preceded by or arises from RPE degeneration is not well understood. In some wet AMD patients, central vision may be lost in a short period of time if choroidal neovascularization or leaky vessels affect the macula. Patients with dry AMD lose their central vision in a relatively slow, progressive manner because of the gradually decreased RPE density. RPE dysfunction and degeneration is common in both forms of the disease (Fig. 1) .
The pathogenesis of AMD is complex and is associated with both genetic components and environmental factors. Thus far, a number of genetic factors have been found to be associated with AMD. Most of these genes, including complement factor H (CFH), C2, C3, CFB, tolllike receptor 3 (TLR3), and toll-like receptor 4 (TLR4), are involved in the complement pathway or related to the immune system. Some mutations of these genes, such as the Y402H polymorphism of CFH (Klein et al., 2005) and 412F variant of TLR3, are well documented to be associated with AMD (Yang et al., 2008) . CFH plays an essential role in the regulation of complement activation, which can be detected in drusen. Mutations in the CFH gene can lead to the destruction of photoreceptor and RPE cells (Collard et al., 2000) . TLR3 can recognize double-stranded RNA (dsRNA), which is also a component of drusen. Excess dsRNA can activate the immune response in photoreceptor and RPE cells, resulting in retinal degeneration (Gao et al., 2017; Murakami et al., 2014) . Environmental factors, such as diet, smoking and light exposure, are also associated with AMD (De Jong, 2006) . Thus, this multifactorial disease exhibits diverse phenotypes in a widespread population.
Currently, retinal degeneration is an irreversible process, and no radical cure is available. Some treatments targeting neovascularization can slow down the progression of vision loss and disease symptoms. In wet AMD, these treatments include injection of anti-VEGF and surgical removal of the neovascular membrane. Several VEGF treatments, such as bevacizumab (Avastin, Genentech), ranibizumab (Lucentis, Genentech/Novartis) and aflibercept (VEGF Trap-Eye, Regeneron/ Bayer), have been shown to be effective for advanced neovascular AMD. However, geographic atrophy, which accounts for the majority of the AMD population, remains incurable. Transplantation of autologous peripheral RPE underneath the macula has provided proof-of-concept evidence that RPE cell replacement can improve visual function, indicating a therapeutic potential for AMD (Binder et al., 2004; van Meurs et al., 2004) . A limited autologous RPE cell source prevents the widespread application of this method. Stem cells, with the potential to differentiate into almost all cell types, have been used for RPE cell generation in a dish. The relevant approaches are discussed below. Nowadays, it is well accepted that stem cell-derived RPE cells provide numerous sources of exogenous RPE for cell replacement (Fig. 2) .
Retinitis pigmentosa
RP is a major cause of blindness in populations below middle age (Al-Merjan et al., 2005; Buch et al., 2004) , affecting over 2 million people worldwide (Strauss, 2005) . The age of RP patients varies from infancy to middle age, and their phenotypes are highly variable. These patients may experience night blindness to severe vision loss with the development of the disease; by age 40, most patients are legally blind (Hartong et al., 2006) . Night blindness is caused by primary loss of rod photoreceptor cells, which are responsible for peripheral and low-light vision. With the progression of the disease, subsequent cone degeneration leads to central and color vision loss.
RP is an inherited retinal degenerative disease that exhibits exceptional genetic heterogeneity. RP disease-causing genes can be categorized into eight main classes based on their biological functions, including the phototransduction cascade, vitamin A metabolism, RNA intron-splicing factors, structural or cytoskeletal roles, synaptic interaction, intracellular trafficking, pH regulation, cilia maintenance and RPE phagocytosis (Hartong et al., 2006) . At present, more than 4500 mutations in approximately 70 disease-causing genes have been identified (Ran et al., 2014) (http://retinogenetics.org/). Recently, new RP-associated genes were found following the application of next- In dry AMD, the formation of drusen can be observed between the RPE and Bruch's membrane (BM), causing RPE and photoreceptor cell degeneration. Wet AMD is characterized by the invasion of abnormal, leaky choroidal blood vessels and the accumulation of macrophages in the RPE cell layer, which also lead to degeneration of the RPE and photoreceptor cells. Drusen, MACs, and ghost vessels are also observed. Green dots indicate MACs. INL, inner nuclear layer; ONL, outer nuclear layer; M, microglia; CNV, choroidal neovascularization. (B) In RP, photoreceptor or RPE cell degeneration results from gene mutations that specifically function in the photoreceptor (e.g., RPGR, RHO) or RPE (e.g., RPE65, MITF) cell. (C) Elevated intraocular pressure is indicated by arrows (left). RGC degeneration caused by increased intraocular pressure is observed in glaucoma patients (right). generation sequencing . These findings provide a molecular basis for improving approaches for clinical genetic diagnosis (Huang et al., 2015a (Huang et al., , 2015b ). An investigation of a large cohort in a single North American eye clinic found disease-causing genotypes with a sensitivity of 76% using genetic testing . Despite the increasing number of identified disease-causing genes, not all RP patients can be revealed the genetic predispositions in known genes.
In most cases, vision loss in RP is due to photoreceptor cell or RPE cell degeneration caused by gene mutations. Since the underlying mechanism of cell death is largely unclear, few effective treatments have been developed. Dietary supplementation is highly recommended by many physicians for patients with early-stage RP to slow disease progression. Several other strategies to treat advanced RP patients are being assessed in clinical trials. Transplantation of an artificial retina, the Argus II Retinal Stimulation System, has been approved by the FDA and has improved long-term visual function in late-stage RP patients (Da Cruz et al., 2013; Luo and Da Cruz, 2016) . Another method involves the transplantation of ARPE-19 cells expressing neurotrophic factors (such as ciliary neurotrophic factor, CNTF) (Birch et al., 2016; Kauper et al., 2012; Sieving et al., 2006) . Gene therapy to target patients with specific mutations using AAV2 has been applied in the treatment of Leber's congenital amaurosis (LCA), which is caused by an RPE65 gene mutation (Ashtari et al., 2017; Bennett et al., 2016; Drack et al., 2016; Hauswirth et al., 2008; Maguire et al., 2009) . The CRISPR/Cas9 system also has great potential as a therapeutic treatment for retinal degenerative diseases. An AAV-based CRISPR/Cas9 system was used in a retinal degeneration mouse model and improved photoreceptor survival by disrupting Nrl expression in postmitotic photoreceptors (Yu et al., 2017) . In a rat model carrying the dominant S334ter mutation in the Rhodopsin gene, subretinal injection of guide RNA/Cas9 plasmid could prevent retinal degeneration and improve visual function (Bakondi et al., 2016) . Relative to these methods, cell-replacement therapy is considered a competitive approach for widespread application. For patient-derived iPSCs, CRISPR/Cas9 genome editing strategies can also be integrated to correct genetic defects before transplantation (Burnight et al., 2017; Deng et al., 2018) . Taken together, regeneration strategies for RP via replenishment of prosthesis, neurotrophic factors, forced gene expression have been extended to human trials, and gene editing or cell replacement is underway on pre-clinical studies.
Stargardt's disease
Stargardt's disease, characterized by the deposition of lipofuscin-like substance in RPE with secondary photoreceptor cell death in the macula (Sunness, 2015) , is an inherited blinding disease (Allikmets et al., 1997) . Mutations most frequently occur in the ABCR gene (also known as ABCA4), which consists of 50 exons and encodes a 2273-amino-acid protein (Broccardo et al., 1999) . ABCR is a retina-specific ATP-binding cassette (ABC) protein that plays a key role in retinoid cycling. Dysfunction of this gene leads to the accumulation of N-retinylidene-Nretinyl-ethanolamine (A2E), a major component of lipofuscin, in RPE cells (Allikmets et al., 1997; Mata et al., 2000; Weng et al., 1999) . The accumulation of A2E appears to be responsible for the loss of photoreceptor and RPE cells, leading to severe vision loss in patients. In a mouse model of recessive Stargardt's macular degeneration, treatment with isotretinoin inhibits A2E formation and lipofuscin accumulation (Radu et al., 2003) . Thus far, however, no effective treatment is clinically available to slow the progression of Stargardt's patients. It has been recently proposed that cell replacement therapy may compensate for the current lack of therapies for Stargardt's disease. In the last decade, two studies have made the attempt to transplant human ESCderived RPE into subreitnal space of patients with Stargardt's macular dystrophy, indicating a promising treatment for this disease (Schwartz et al., 2012 (Schwartz et al., , 2015 .
Glaucoma
Glaucoma is the most prevalent neurodegenerative disease, affecting more than 70 million people worldwide (Quigley and Broman, 2006) . The etiology of glaucoma is relatively complex, and signs of glutamate toxicity, oxidative stress, and reactive glial changes are observed in glaucoma patients (Gupta and Yücel, 2007) . Intraocular pressure is determined by the dynamic flow and drainage of aqueous humor secreted by the ciliary body. The trabecular meshwork and uveoscleral outflow pathways are the two independent pathways for aqueous humor drainage. Both dysfunction of the trabecular meshwork and anatomic location abnormality of iris blocking the trabecular meshwork can lead to two different kinds of glaucoma, designated open-angle glaucoma and angle-closure glaucoma. Presently, control of intraocular pressure by medication and eye surgery are the main verified treatments slowing down the disease progression. Although these treatments can delay the development of the disease, they cannot prevent neurodegeneration eventually (Bull and Martin, 2011) and vision impairment resulting from optic nerve damage and RGC loss is irreversible. Bone marrow MSCs can exert neuroprotective effects and promote the survival of RGCs in aged rats with glaucoma . Although neuroprotection of MSCs can provide another potential treatment option for glaucoma, it is much more difficult to regenerate RGC and optic nerve beyond paracrine effect in cell replacement strategy.
Derivation of specific retinal cells from pluripotent stem cells
Retinal tissue cell derivation
RPE cell induction
RPE dysfunction causes severe vision impairment in patients with geographic atrophy or RP. Autologous RPE cell replacement has provided proof-of-concept evidence that cell therapy may have promising applications for retinal degenerative diseases. However, the RPE cell source is restricted for applications in RPE cell replacement because of the limited number of donor eyes and ethical issues. Pluripotent stem cells, including embryonic stem cells (ESCs) and iPSCs Takahashi and Yamanaka, 2006; Thomson et al., 1998; Yu et al., 2007) , are self-renewable and have the potential to differentiate into the cell types of ectoderm, entoderm, and mesoderm, such as RPE cells, photoreceptor cells, and RGCs. The generation of pluripotent cells and establishment of somatic differentiation in vitro provide unlimited cell sources for cell replacement.
Different methods for the derivation of ESC-RPE cells have been approached, and each method possesses both advantages and disadvantages. We have described two approaches for RPE cell differentiation from ESCs, including stromal cell-derived inducing activity (SDIA) (Kawasaki et al., 2000 (Kawasaki et al., , 2002 and small-molecule induction (Osakada et al., 2009b) . Using SDIA induction, we successfully induced mouse ESCs and primate ESCs into dopaminergic neurons and Pax6 + -pigmented epithelial cells of the retina. After 3 weeks of differentiation, 8 ± 4% of primate ESC colonies (n = 200) induced by SDIA contained large patches of RPE cells (Kawasaki et al., 2002) . These SDIA-induced RPE cells have the properties and functions of real RPE cells in vivo. ESC-RPE cells possess a hexagonal morphology, express RPE markers, such as ZO-1, MITF, and RPE65, and have extensive microvilli that can phagocytose latex beads (Haruta et al., 2004) . However, the disadvantages of this method include the undefined culture conditions and the low efficiency of RPE cell induction. Fortunately, several defined and high-efficiency culture methods have been developed to overcome these drawbacks; one of the most important methods is small-molecule induction. We showed that inhibition of Wnt and Nodal signaling by small molecules, such as CKI-7 and SB431542, was able to induce RPE cell formation from human ESCs. After 2 months of induction, 26 ± 4% of hESC colonies and 18.1 ± 1.9% of total cells differentiated into RPE cells (Osakada et al., 2009b) . Another method involving the addition of nicotinamide and activin A significantly promoted the differentiation of hESCs into RPE cells. After 8 weeks of differentiation, approximately 72.9 ± 2.5% of hESC colonies exhibited the squamous and hexagonal morphology characteristics of RPE cells.
The morphological characteristics of hESC-RPE cells, including apical microvilli, melanin granules, basal membranes and tight junctions, were remarkably similar to those of authentic RPE cells in vivo (Idelson et al., 2009 ). Transplantation of hESC-derived cells requires immunosuppression for approximately three months (Schwartz et al., 2012 (Schwartz et al., , 2015 Song et al., 2015) , during which time patients are at risk for infection and side effects. In contrast, autologous transplantation of iPSC-derived cells has better histocompatibility than allogeneic transplantation of cells. To design a better preclinical study, similar to the methods used for ESC-derived RPE cell differentiation, we first established protocols for iPSC-RPE derivation in animal models, such as primates and mice (Iwasaki et al., 2016; Okamoto and Takahashi, 2011) . RP patients' iPSC-derived RPE cells have also been induced to supply an unlimited cell source for disease modeling and future transplantation (Jin et al., 2011; Jin and Takahashi, 2012) . Additionally, defined conditions for RPE induction promote the clinical use of RPE cell therapy (Osakada et al., 2009b; Vaajasaari et al., 2011) . However, both ESC-RPE and iPSC-RPE methods are constrained by a lengthy differentiation process. Therefore, methods with a remarkably reduced culture time or storable RPE cells are needed for future clinical studies.
Regardless of the diverse methods from which RPE cells are derived, certain typical characteristics should be considered. Induced RPE cells should exhibit a hexagonal morphology with ZO-1 + /RPE65
+ and express marker genes involved in pigment synthesis (Tyrosinase, Tyrp1, Tyrp2 and SILVER) and the visual cycle (Rpe65, Lrat, Rdh5 and Rlbp1) in addition to secreted proteins (Transthyretin, CNTF and PEDF) at levels similar to those in RPE cells in vivo (Buchholz et al., 2009; Maeda et al., 2013) . In addition, these cells have extensive microvilli with the ability to phagocytose POS isolated from animal models or from ex vivo human retinal systems (Carr et al., 2009; Idelson et al., 2009) . Judging from its monotonicity and proficient methodology for generation, the RPE cell is considered the best choice for cell replacement therapy.
Neuro-retinal cell differentiation
Retinal progenitor cells, a type of retinal stem cell, can differentiate into various retinal cell types, including photoreceptor cells, RGCs, amacrine cells, bipolar cells, horizontal cells and Müller glia. Using a serum-free floating culture of embryoid body-like aggregates (SFEBq) combined with Wnt and Nodal antagonists (Dkk1 and LeftyA), we promoted the differentiation of mouse ESCs into Rx + /Pax6 + neural retinal progenitor cells (28.3% colonies and 6.4% total cells) (Ikeda et al., 2005) . For human ESCs, following a stepwise differentiation protocol, 20-30% of colonies exhibited Rx/Pax6 positive retinal precursors or Mitf/Pax6 positive RPE progenitors after 30-45 days of differentiation (Osakada et al., 2009a) . This method can also be applied to generate retinal precursor cells (RPCs) from iPSCs. On day 45, mouse iPSC-derived photoreceptors expressed photoreceptor precursor markers Crx and Rhodopsin; the latter marker indicates the presence of mature rod photoreceptors. For human ESCs or iPSCs, differentiation is time consuming. Under defined conditions, the photoreceptor precursor marker CRX was expressed at approximately day 80, and nearly half of RECOVERIN + cells coexpressed the mature rod photoreceptor cell marker RHODOPSIN (Hirami et al., 2009; Osakada et al., 2009a) . Those iPSC-derived photoreceptors can be used as a model to recapitulate the disease mechanisms of RP and provide a suitable cell source for grafts in RP diseases for preclinical studies (Jin et al., 2011; Jin and Takahashi, 2012) . Different methods to promote the differentiation efficiency of retinal precursors and mature photoreceptors have been attempted. When co-cultured with retinal tissues, ES-derived retinal precursors differentiate into photoreceptor cells (Ikeda et al., 2005) . We also established an enrichment protocol for retinal precursors by using a combination of two lectins, wheat germ agglutinin and Erythrina crista-galli agglutinin. Relative to the original SFEBq method, this protocol can double the enriched Rx + retinal precursor population (Ikeda et al., 2005; Mandai et al., 2010) . For mouse ESCs, inhibition of Notch signaling by γ-secretase inhibitor DAPT induces Crx + photoreceptor precursors from Rx + retinal precursors (Osakada et al., 2008) . The addition of a combination of defined factors, including Shh, taurine and retinoic acid, favors the production of Rhodopsin + rod photoreceptors and has no significant effects on the production of cone photoreceptors. Moreover, treatment of monkey and human ESC-derived retinal progenitors with retinoic acid and taurine can induce photoreceptor differentiation (Hirami et al., 2009; Osakada et al., 2008) .
Generation of structured neuro-retinal organoids
With its complex morphogenesis, the neural retina, which contains various cell types connected to multiple synaptic junctions, is unlikely to be repaired by transplantation of a single cell type in patients with end-stage retinal degeneration. The replacement of retinal tissue may inspire potential therapies. Attempts have been made to generate neural retina tissue from pluripotent cells in vitro, and an optic vesiclelike structure containing rhodopsin positive cells can be induced in a 2-dimensional (2D) culture system (Meyer et al., 2011; Phillips et al., 2012; Jin and Takahashi, 2012; Tucker et al., 2013) . Eiraku et al. (2011) generated a well-organized optic cup structure from a 3-dimensional (3D) culture system. In the floating retinal organoids, the three neural retina layers exist in layers similar to those in retinas in vivo, and the photoreceptors in the organoid are more mature than those in a 2D culture system. The 3D cell culture system has been shown to induce the formation of an optic cup from mouse and human ESCs (Eiraku et al., 2011; Nakano et al., 2012) . The ESC-derived optic cup contained the major neural retina components, including photoreceptors, RGCs, and bipolar cells. Based on the self-formation in ESC culture, other protocols for optic-cup generation have also been developed (Kuwahara et al., 2015; Lowe et al., 2016; Völkner et al., 2016) . With timed BMP4 treatment, the efficiency of Rx-positive epithelium was dramatically increased, and the transition from neural retina tissue to RPE was achieved by inhibiting GSK3 and FGFR (Kuwahara et al., 2015) . Recently, culture conditions modified by the addition of B27 were used to supplement Neurobasal-A enhanced neurite outgrowth from RGCs in mouse and human ESC models (Maekawa et al., 2016) .
Similarly, an optic cup with RGC cells can be generated from human iPSCs (Zhong et al., 2014) . The method was modified to generate functional RGCs from human iPSCs, mouse ESCs and mouse iPSCs by combining 3D and 2D cultures; typical RGC action potentials have been recorded in these optic cups (Tanaka et al., 2015 (Tanaka et al., , 2016 . A recent study demonstrated that human iPSCs seeded on an engineered scaffold can grow dendritic arbors and functional axons; this approach is promising for clinical translation in the future .
The neural retina develops from the optic vesicle to the optic cup, but the mechanism of optic-cup organogenesis remains elusive. Notably, reports have shown that 3D culture can induce the formation of an optic cup and ciliary epithelium from mouse ESCs and mouse iPSCs, respectively, under the corresponding differentiation conditions (Eiraku et al., 2011; Kinoshita et al., 2016) . The connecting cilium, located between the inner and outer segment, is a critical structure for material transfer in photoreceptors. The generation of 3D retina with the connecting cilium and outer segments makes this tool a powerful one for modeling RP, and mature photoreceptor cells are expected to benefit for visual rescue after transplantation (Deng et al., 2018; Parfitt et al., 2016; Shimada et al., 2017; Wahlin et al., 2017) . For therapeutic application, Reichman et al. (2017) developed a completely defined condition for retinal organoid differentiation from human iPSCs. The removal of animal derivatives is a key improvement for the clinical transplantation of retinal tissue. Even though the optic-cup structure can be generated in many laboratories, the presence of photoreceptors with outer-segment discs, electrophysiological properties, and light sensitivity have been reported by only a few groups (Deng et During retinal development, the fates of various cell types are controlled by transcription factors in a precise spatiotemporal order (Cepko, 2014) . Understanding the profile of transcriptional and epigenetic changes that occur during retinogenesis is expected to assist in optimizing methods for generating more mature retinal organoids in vitro. Kaewkhaw et al. (2015) analyzed the transcriptome of 3D retinal organoids, profiling temporal changes in gene signatures at different stages. Additionally, the identification of specific cell surface markers provides guidelines for the purification of developmental photoreceptors of different stages. These transcriptional data are helpful for delineating gene regulatory networks during retinal development. However, the stage-by-stage regulatory processes during development of real human retina have been unrevealed in the long history. Recently, two studies have filled this gap (Aldiri et al., 2017; Hoshino et al., 2017) . Hoshino et al. (2017) provided a comprehensive molecular analysis of fetal retina and characterized the cellular basis of foveal development. Aldiri et al. (2017) focused on the dynamics of epigenetics and transcriptomics during retinogenesis in humans. These studies provide an epigenetic and transcriptional map that serves as a reference for molecular staging of human stem-cell derived retinal organoids.
Mesenchymal stem cells
MSCs, which have the ability of self-renewal and differentiation, can be isolated from a variety of tissues, including bone marrow and adipose tissue. Due to their ease of isolation, the characteristics of MSCs have been investigated for two decades. The following features of MSCs make them a promising candidate for the treatment of neural degenerative diseases: neuroprotective properties, differentiation potential and lack of immune rejection . MSCs have been injected into the subretinal space of retinal degenerative animal models, which will be discussed in the following section of this review (Emre et al., 2015; Johnson et al., 2010) . Although the underlying mechanism is unclear, visual function improvement was observed shortly after MSC transplantation. Neurotropic factors secreted by MSCs, such as brainderived neurotrophic factor (BDNF) and CNTF, may protect degenerating cells. Moreover, the immunomodulating properties of MSCs may prevent an excessive immune response in the degenerating retina.
Transdifferentiation of retinal cells
Transdifferentiation, or the conversion of one cell type into another without redifferentiation of pluripotent stem cells, is a potential way to generate patient-specific cells/tissues. Direct neuronal conversion of fibroblasts has been achieved by forced expression of transcription factors in mice and humans (Pang et al., 2011; Vierbuchen et al., 2010; Kim et al., 2011) . Recently, the small-molecule induction of cell reprogramming and transdifferentiation has made breakthrough progress, which has been previously reviewed (Hou et al., 2013; Xu et al., 2015) . Functional neurons and cardiomyocytes can be generated from fibroblasts under chemically defined conditions (Ambasudhan et al., 2011; Cao et al., 2016; Zhang et al., 2016) . However, direct induction of retinal cells is seldom studied. In the developing murine retina, misexpression of Chx10 leads to direct transdifferentiation of retinal cells into nonpigmented RPE, supporting the potential for RPE transdifferentiation (Rowan et al., 2004) . A recent study showed that retinal neurons can be generated from Müller glia in adult mice after NMDA damage by forced expression of the Ascl1 gene together with a histone deacetylase inhibitor TSA (Jorstad et al., 2017) . These findings demonstrated the potential for cellular reprogramming, thus providing a new approach for the treatment of retinal disease.
Preclinical trials
RPE cell replacement
The atrophy of RPE cells accounts for a part of retinal degeneration. Jin, et al. Progress in Retinal and Eye Research 69 (2019) 38-56 Currently, the two major strategies for replacing atrophic RPE cells include an RPE cell suspension and an RPE cell sheet. When a suspension of human RPE cells (ARPE-19) was grafted into RCS rats, the cells spread along the host RPE cells and rescued the photoreceptor cells (Wang et al., 2005) . Considering the capability of human RPE cells to rescue photoreceptors to some extent, their additional physiological functions warrant further study. Transplantation of hESC-RPE cells in RCS rats resulted in functional and structural recovery of the severely impaired retina. Carr et al. (2009) found that transplanted hESC-RPE cells were capable of phagocytosing photoreceptor debits in RCS rats. For safety reasons, in the rat and mouse models, lifelong data were collected, and no evidence of teratoma formation was found (Lu et al., 2009) .
Considering that the RPE cell sheet has extracellular matrix and adhesion molecules that prevent apoptosis, RPE cell sheet transplantation is better than cell suspension transplantation for the treatment of AMD. Transplantation of autologous iPSC-derived RPE cell sheets in nonhuman primates showed no rejection signs and no tumor formation, indicating that cell sheets might be a preferable form of cell replacement therapy for AMD . BM is an important structure for maintaining healthy homeostasis of the retina and supporting RPE cell adhesion, differentiation and migration. To mimic the support of BM in vitro, supportive scaffolds are created from various materials, including organic polymers, biomaterial nanofibers and biodegradable biomaterials. Polyethylene terephthalate or poly (L-lactide-co-ε-caprolactone) or collagen type I and poly (lactic-co-glycolic acid) (PLGA) (Warnke et al., 2013) were subjected to electrospinning, and fiber membranes were tested for RPE cell survival in vitro and biocompatibility in animal models. We identified a novel biomaterial, regenerated wild Antheraeapernyi silk fibroin (RWSF), on which to seed RPE sheets. RWSF combined with polycaprolactone (PCL) and gelatin (Gt) was fabricated into an ultrathin, porous, nanofibrous membrane using electrospinning . Similarly, others (Jin et al., 2009; Liu et al., 2014) have taken full advantage of the biodegradable properties of a blend of hyaluronan and methylcellulose (HAMC) and used it to support primary mouse retinal stem/progenitor cell survival and differentiation (Ballios et al., 2010) . All these materials are suitable substrates for supporting living RPE cells and their functions. However, the long-term survival of RPE cells in the subretinal space and inflammation or rejection after transplantation requires further study.
Some traditional artificial scaffolds cause inflammation and separate the RPE from the choroid, severely degrading the effect of transplantation. Therefore, RPE cell sheets that meet clinical requirements, including quality, quantity, consistency and safety, are needed. A monolayer RPE cell sheet was prepared on type I collagen gel and digested with collagenase I. These clinical grade RPE cell sheets express typical RPE makers, have phagocytotic ability, and exhibit gene expression profiles similar to those of native RPE (Fig. 3) . Autogenic grafts are safe but expensive and unable to be used to treat acute patients. A human leukocyte antigen (HLA)-matched cell source could be a better choice, considering the costly and timeconsuming differentiation of RPE cells. We recently found that T cells failed to respond to HLA homozygous iPS-RPE. Transplantation of major histocompatibility complex (MHC)-matched allografts into a monkey model resulted in no immune rejection and could be performed without immunosuppression. These MHC homozygous options could be used to treat AMD in histocompatible recipients in the future (Sugita et al., 2016a (Sugita et al., , 2016b .
The secretion of CNTF by transplantation of cell-containing capsules has been shown to provide neurotrophic rescue effects in PDE6B-deficient canine models injected through the vitreous (Tao et al., 2002) . However, grafts of hESC-RPE cells injected in the vitreous failed to show similar trophic effects or photoreceptor rescue in nine transplanted RCS rats. Subretinal injection of the same hESC-RPE cells rescued retinal structure and function in the same animal model (Idelson et al., 2009 ). These results indicate that integration of the transplanted hESC-RPE cells into the subretinal space is critical for long-term retinal function restoration, but not its neurotrophic effects.
Photoreceptor transplantation
Photoreceptor precursor transplantation is a potential way to treat retinal degenerative diseases caused by photoreceptor loss, such as RP and AMD. For most patients with RP, rod photoreceptor death is the primary cause of night blindness in the early disease stage. In addition, rods account for more than 90% of photoreceptors; thus, rod photoreceptor transplantation is a suitable treatment for RP. In the late stage of AMD, photoreceptor loss is also accompanied by RPE dysfunction. Thus far, rod photoreceptor precursor transplantation has been accomplished in retinal degenerative mouse models using photoreceptor precursor cells derived from the newborn mouse retina, or retinal organoid-derived from ESCs or iPSCs. Among these cell sources, Nrl-GFPlabeled rod precursors isolated from postnatal day 4-8 Nrl-GFP mice have frequently been used in photoreceptor transplantation (MacLaren et al., 2006; Pearson et al., 2012; Singh et al., 2013) . In rho −/-mice, transplanted rod precursors were found to migrate into the ONL of adult mice and form synaptic connections. In addition, rhodopsin expression was also observed in donor cells, indicating the maturation of the transplanted precursor cells (MacLaren et al., 2006) . Improvement has been achieved by transplantation of a maximum of approximately 30,000 integrated cells distributed across more than 50% of the gnat1 −/− mouse retina. Relative to the results of a previous study achieving approximately 1000 integrated rods, this integration number increased by 20-to 30-fold. Although the ERG manifestation and visually guided behavior remained unchanged, the improved light response supports the potential of this method . To overcome the limited supply of donor eyes, iPSC-derived photoreceptors have been used for preclinical transplantation. A previous report demonstrated that iPSC-derived photoreceptors are a viable source for the production of photoreceptor precursors for cell replacement (Tucker et al., 2011) . Photoreceptor precursors generated from mouse ESCs using a 3D differentiation protocol were transplanted into gnat1 −/− mice (Gonzalez-Cordero et al., 2013; Tucker et al., 2011) .
The transplantation of isolated precursors into six genetic mutation mouse models resulted in highly variable phenotypes. The effects of rod photoreceptor transplantation were affected predominantly by the following factors: different genetic defects, outer limiting membrane (OLM) integrity and glial scarring (Barber et al., 2013) . In addition, human iPSC-derived photoreceptors have been tested in mouse, which is a well-suited model to test the safety of a cell source before clinical application (Lamba et al., 2010) . Rod precursors differentiated from hESCs and iPSCs could regenerate a new photoreceptor layer in rd1 hosts and restore the visual function of blind mice, with repair of the visual circuit (Barber et al., 2013; Lamba et al., 2009 ). In our study, photoreceptor precursor cells isolated from 3D retina organoids derived from human ESCs, labeled with td-Tomato under the CRX promoter, were transplanted into the subretinal space of wild-type C57/BL6/J mice. Human photoreceptor precursors could also integrate into mouse retina and develop into rod-and cone-like photoreceptor cells (Fig. 4 , unpublished data). For enrichment of integrated cells, transplanted photoreceptor precursors cells isolated from neural retinas of Nrl-GFP mouse eyes or ESC-derived 3D retinas by sorting with cell surface marker panel could integrate more successfully than transplanted unsorted ones (Lakowski et al., 2011 (Lakowski et al., , 2015 . This procedure also decreases the number of detrimental proliferating cells (Lakowski et al., 2015) . Recently, Lakowski et al. further extended this solution using a high-throughput flow cytometry approach and identified a combination of cell surface biomarkers for photoreceptor sorting from both human fetal retina and hESC-derived organoid cultures (Lakowski et al., 2018) . Besides, immunosuppression may be useful to promote the efficiency of clinical cell transplantation. West et al. (2010) found that macrophages and T cells might be correlated with a reduction of integrated photoreceptors and that immune suppression could significantly increase photoreceptor cell survival. Immunodeficiency in mice, specifically in the IL2 receptor gamma knockout mouse model, was found to improve integration success after transplantation of hESC-derived photoreceptors. Transplanted cells differentiated into mature photoreceptor cells and restored functional vision for more than 9 months in Crx tvrm65 /IL2rγ −/-mice (Zhu et al., 2017) . The physiology and function of the donor cells still need to be adequately defined after the integration and differentiation of developing photoreceptor cells. In the wild-type mouse retina, GFP-labeled rods derived from developing mouse retinae or iPSCs exhibited Ca 2+ responses and membrane currents at a level similar to that of native rod photoreceptors (Homma et al., 2013 . Recently, with improvements in the imaging and analysis of transplant recipients, donor cell fluorescent reporters can be used to characterize both cell integration and material exchange between donor and host cells (Waldron et al., 2018; Warre-Cornish et al., 2014) . Using twocolor fluorescence, EdU pre-labeling, and Y-chromosome FISH, among other techniques, several studies have demonstrated that the majority of donor-reporter-labeled cells result from material transfer Ortin-Martinez et al., 2017; Pearson et al., 2016; Santos-Ferreira et al., 2016; Singh et al., 2016) . Understanding this novel mechanism may benefit predetermination of the duration of rescue based on the half-life of the particular gene or protein. However, no consistent conclusions have been identified concerning whether material transfer actually consists of cytoplasmic transfer, free protein/ RNA uptake or cell fusion (Ortin-Martinez et al., 2017; Pearson et al., 2016; Singh et al., 2016) . A determination that material exchange dominates over cell integration during photoreceptor transplant may facilitate the reinterpretation of previous functional rescue data and offer new approaches to vision rescue (Nickerson et al., 2018) .
Retinal sheet transplantation
In the end stage of retinal degenerative diseases, the degenerative area expands from peripheral areas toward central areas, with a substantial "ONL-depleted area" in many patients. In this circumstance, transplantation of a single cell type is unlikely to restore vision. Retinal sheet transplantation was performed in both animals and human decades ago using retinal sheets dissected from fetal donor eyes. The restoration of visual responses in the transplant demonstrated that the connectivity between the implant and host contributed to visual improvement, supporting the use of retinal sheet transplantation to cure late-stage retinal degenerative diseases (Seiler and Aramant, 2012) . The development of protocols for 3D differentiation of retinal organoids has allowed the preparation of retinal tissue for clinical retinal grafts. Transplantation of a structured optic vesicle derived from autologous iPSCs and ESCs in rd1 mice led to the formation of a complete inner segment/outer segment (IS/OS) and host-graft synaptic connections, even improving visual functions such as light-responsive behaviors and ganglion cell recordings in host mice (Fig. 5) (Assawachananont et al., 2014; Mandai et al., 2017a) . After transplantation of retinal tissue derived from human ESCs in nude rats and two RP monkey models, we observed graft maturation into the ONL and host-graft synaptic (Adapted from Kamao et al., 2017; Osakada et al., 2009b) .
connection formation in the primate models (Shirai et al., 2016) . To exclude the possibility of material transfer and prevent immune rejection at the same time, Iraha et al. (2018) established mouse models of end-stage retinal degeneration with immunodeficiency. After transplantation of the hESC-derived retinal sheet for approximately 200 days, maturation and integration of transplanted cells were observed, forming an IS/OS structure and synaptic connections without rejection. Although several light-responsive RGCs were recorded using the multielectrode assay, a full-field ERG response was not detected, which is attributed to an insufficient number of mature photoreceptor cells in the transplanted retina. These studies provide proof-of-concept evidence for the transplantation of retinal tissue derived from ESCs/iPSCs to treat end-stage retinal degeneration. However, the application of retinal grafts still faces obstacles in terms of the generation of laminated retinal tissue and the connectivity between transplanted tissue and host neural cells.
Ganglion cell transplantation
Progressive RGC death is a typical characteristic observed in patients with glaucoma. However, most stem cell translational studies focused on RPE and photoreceptor regeneration. Several studies have addressed the protocol for RGC differentiation from stem cells and their transplantation in RGC-driven diseases, such as glaucoma. Two formidable challenges are the migration of implanted RGCs through the ONL to the inner retina and the formation of precise synaptic connections targeting the sub-cortical areas. Successful differentiation of RGC precursors from human Müller glia cells (hMGCs) has been achieved by transient inhibition of Notch activity (Rapaport and Dorsky, 1998) . Transplantation of RGC precursors derived from hMGCs could improve the negative scotopic threshold response of the ERG, which indicates RGC function in mouse and feline models of RGC depletion (Becker et al., 2016; Singhal et al., 2012) . Functional and mature RGCs have also been generated from pluripotent stem cells under chemically defined conditions, providing an unlimited cell resource for cell replacement therapy (Jagatha et al., 2009; Parameswaran et al., 2010; Riazifar et al., 2014) . Transcriptional analysis of RGCs derived from human pluripotent stem cell lines were performed by Langer et al. (2018) . Their findings may facilitate the classification of RGC subtypes and the identification of cell markers for different subtype classes. A great number of RGCs in 3D organoids are derived from pluripotent stem cells. We will not discuss the details regarding the protocols for RGC generation and the characteristics of pluripotent stem cell-derived RGCs, which have been previously reviewed (Gill et al., 2014) . However, many problems remain unsolved, such as finding an appropriate way to deliver RGCs while avoiding significant damage to photoreceptors, improving the efficiency of migration and integration and sustaining visual function for an extended time after transplantation.
MSC transplantation
MSCs have been proposed as a potential cell source for transplantation-based approaches to treat retinal degenerative diseases. The transplantation of MSCs derived from both adipose tissue and bone marrow has neuroprotective effects in RGC degenerative animal models (Emre et al., 2015; Inoue et al., 2007; Johnson et al., 2010) . In addition, the numbers of both RGCs and RGC axons are significantly increased in a short period time after MSC transplantation (Harper et al., 2011; Johnson et al., 2010) . RGC protection has also been functionally demonstrated in aged rats with glaucoma that can finish swimming tests with visual guidance cues better after transplantation of bone-marrowderived stem cells (BMSCs) (Hu et al., 2013) . The surgical method for MSC delivery also affects the survival time of MSCs in host eyes and the therapeutic effect of MSCs in RCS rats. In subretinal injection treated eyes, retinal function can be significantly better than in control eyes for up to 20 weeks, whereas this improvement can be found for only up to 12 weeks in intravitreally injected eyes (Tzameret et al., 2014) . In RP animal models, transplantation of bone marrow-derived MSCs can preserve ONL cells, prolonging photoreceptor survival (Arnhold et al., 2007) . Thus, subretinal injection of MSCs may benefit not only RGCs but also photoreceptor cells, whereas the strength and duration of the protective effect remain unclear.
Several possible mechanisms related to protective effect of MSCs transplantation have been described and emphasized (Cselenyak et al., 2010; Mead et al., 2017) . Trophic support and immunosuppression of MSCs have been well studied. Those characteristics of MSCs have been linked to the paracrine effects which exerted by the transplanted cells. Local injection of MSCs had neuroprotective effects for different models of retinal degeneration. It is indicated that MSCs can express a variety of factors which could protect injured retina, such as NGF, CNTF, BDNF, bFGF, and IGF1 (Lin et al., 2009; Johnson et al., 2010) . Johnson et al. (2010) found that MSC transplantation exerted protective effects on optic nerves in a model of glaucoma by directly protecting RGCs and their axons. They postulated that the most likely mechanism for the protection was through the secretion of NTFs by the grafted MSCs (Torrente and Polli, 2008) . Furthermore, other paracrine factors produced by MSCs have been linked to anti-inflammatory (Milner et al., 2006; Wisniewski et al., 2004) , immunomodulatory (Ghannam et al., 2010) , collateral perfusion and neovascularization processes in the ischemic region (Kinnaird et al., 2004; Tang et al., 2006) . However, whether paracrine effect of MSCs is a key mechanism in host retinal cell protection/rescue is still under debate.
Over the last decade, evidence has been accumulated to show that MSCs might exert their therapeutic effects via intercellular transfer through tunneling nanotubes (TNTs) (Gerdes and Carvalho, 2008; Lou et al., 2012) . Jiang et al., 2016 provided the first in vitro and in vivo evidences that mitochondria could be transferred from iPSC-MSCs to corneal epithelial cells with acquired mitochondrial defects and rescued cells from death. However, they indicated that the beneficial effect of intercellular mitochondrial transfer is independent of paracrine factors of MSCs using a Transwell assay. The role of mitochondrial transfer of MSCs and therapeutic mechanism of mitochondrial transfer in a retinal setting has never been studied before. No doubt that further study of interactions between MSCs and host tissue may yield unexpected results, either from the perspective of understanding the therapeutic mechanism of stem cell or the broad range of application. Kinoshita et al., 2016; Mandai et al., 2017a) .
Table 1
Status of registered clinical trials (reported) using stem cell-derived cells for retinal degeneration. 
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Completed and ongoing clinical trials
Human embryonic stem cell derived RPE (hESC-RPE) cells, MA09-hRPE (Advanced Cell Technology Inc., California, USA), have been used in four clinical trials (NCT01674829, NCT01344993, NCT01345006 and NCT01625559) ( Table 1) . These clinical trials were carried out in the USA and the Republic of Korea, involving patients with AMD or Stargardt's disease. Based on their reports, improvements in visual acuity were observed in patients with AMD and Stargardt's disease in both short-term (< 4 months) and long-term (12-22 months) followups. Visible subretinal pigmentation representing integration of transplanted RPE cells has been observed in fundus photography and OCT (Schwartz et al., 2012 (Schwartz et al., , 2015 Song et al., 2015) . In AMD patients, preretinal pigmentation in 3 eyes in the US trial and preretinal pigmentation with an epi-retinal membrane (ERM) in 2 patients in the Korean trial have been detected. The visual acuities of three patients were improved or maintained after the operation. Histological analysis demonstrated that hESC-derived cells might participate in the formation of ERM (Shim et al., 2017) . Regarding safety concerns, hyperproliferation, tumorigenicity or ectopic tissue formation were not detected in any of these patients (Schwartz et al., 2012 (Schwartz et al., , 2015 Song et al., 2015) . Da Cruz et al. (2018) reported the successful delivery of the hESC-RPE patch in two patients with severe wet AMD (NCT01691261). Polyethylene terephthalate (PET) membranes with a thickness of 10 μm were coated with plasma-derived human vitronectin for RPE patch preparation. Following preclinical mouse and pig transplantation studies, RPE patches with a size of 6 × 3 mm were placed in the subretinal space under the fovea. As demonstrated by OCT and fundus photography, the transplanted cells survived and migrated to the host. Improvements of visual acuity and reading speed were observed in the two patients. As indicated by the fundus photographs, the subretinal choroidal neovascular membrane was removed after transplantation. Therefore, whether the visual improvement resulted from the RPE transplantation or the effect of removal of the original choroidal neovascular membrane is ambiguous. Fourteen additional ongoing or recruiting clinical trials using hESC-RPE are registered on Clinicaltrials. gov, which are not discussed herein due to limited information without published reports.
Takahashi's group activated a clinical trial involving the use of autologous induced pluripotent stem cell-derived RPE (iPSC-RPE) cells to treat macular degeneration in 2014 (University Hospital Medical Information Network Clinical Trials Registry [UMIN-CTR] number, UMIN000011929). This clinical trial was the first to use iPSC-derived cells since the initial generation of iPSCs in 2006 (Cyranoski, 2014; Takahashi and Yamanaka, 2006) . Patients' iPSCs were generated from skin fibroblast cells using non-integrating episomal vectors and differentiated into RPE cell sheets according to a validated protocol . The transplanted RPE cell sheet remained intact after one year (Fig. 6) . Visual acuity did not improve or worsen, and no hyperproliferation or tumorigenicity was found. We are not surprised by the lack of improvement in vision since the degeneration of photoreceptor cells is irreversible; RPE transplantation cannot treat this issue. Notably, no signs of rejection were observed even without the use of any immunosuppressants (Mandai et al., 2017b) . Three clinical trials using iPSC-RPE cells are registered on Clinicaltrials.gov; NCT02162953 and NCT01432847 are actively recruiting, and NCT02464956 has not been updated for two years.
Autologous MSCs are also being used in clinical trials (Table 1) due to their neuroprotective, immunomodulatory and regenerative properties. BMSCs are preferred by investigators and are more commonly used for the treatment of retinal degeneration than adipose-derived stem cells (ADSCs). Eleven clinical trials have used BMSCs, and only two have used ADSCs (Table 1) . Siqueira et al. conducted three Phase I clinical trials (NCT01518127, NCT01068561 and NCT01518842) using intravitreal injection of BMSCs containing CD34 + cells. During a 12-month follow-up analysis, patients with AMD (NCT01518127) exhibited improved visual acuity at 3, 6, 9 and 12 months after injection (Cotrim et al., 2017) . A Phase II clinical trial (NCT01560715) was activated with 20 patients with RP in 2012, and the quality of life of patients was improved at 3 months but not sustained at 12 months after injection (Siqueira et al., 2015b) . Among these patients, one with ischemic macular edema obtained persistent improvement in visual acuity and decreased macular edema (Siqueira et al., 2013 (Siqueira et al., , 2015a . Another group from the University of California-Davis Eye Center isolated CD34 + BMSCs and performed intravitreal injection of 3.4 × 10 6 cells in a 0.1 ml suspension, far exceeding the number of 1.68 × 10 4 cells in a 0.1 ml suspension used by Siqueira et al. (Cotrim et al., 2017; Park et al., 2015) . Six patients with AMD exhibited no improvement in visual acuity, while no complications were observed . Weiss et al. enrolled patients with different retinal diseases and performed combined treatment approaches, including retrobulbar, subtenon, intravitreal, intra-optic nerve, subretinal, and intravenous injections of autologous BMSCs according to the features of the different diseases (NCT01920867). The reported results showed remarkable improvement in the visual field and visual acuity (Weiss et al., 2015a (Weiss et al., , 2015b . One clinical trial using ADSCs has been withdrawn (NCT02024269), within which the results for three involved patients have been reported. Severe complications and vision loss, which might due to the stem cell preparation, occurred in three patients (Kuriyan et al., 2017) . The diverse results obtained after BMSC/ADSC transplantation might be due to the quality and quantity of the injected cells. Thus, standardization for BMSC and ADSC preparation is an urgent task for scientists and clinicians. Human central nervous system stem cells (CNS-SCs) have also been used to treat AMD, for which three clinical trials (NCT01632527, NCT02467634 and NCT02137915) are relevant. Ludwig et al. reported two cases of posterior retinotomy closure following subretinal injection of stem cells to treat AMD (NCT01632527). Their study indicates that CNS-SCs might improve retinal wound closure (Ludwig and Leng, 2016) . The other two clinical trials (NCT02467634 and NCT02137915) were terminated due to business reasons. Moreover, human RPCs might be a preferable option for retinal cell replacement. However, only three clinical trials are active at present (NCT02320812, NCT03073733 and NCT02464436), and no results have been reported. Human fetal-derived RPCs were tested for safety concerns in RCS rats prior to use in RP patients. Liu et al. did not observe tumorigenesis in animal models or patients. Improved visual acuity was observed in patients between 2 and 6 months after RPC transplantation but not at 12 months . The authors did not address why the improvement of visual acuity was not maintained over the long term. Based on their ophthalmological examinations, the thickness of transplanted cells was significantly reduced 1 month after surgery, and injected cells could not be observed at 12 and 24 month post-injection. These results indicated that the injected human fetal-derived RPCs could not integrate into the host retina. The short-term visual improvement might be due to the neurotropic effects of fetal retinal cells.
Thus far, all cell therapy clinical trials targeting retinal degeneration are in Phase I/II, and there is insufficient evidence to support their effectiveness. Therefore, clinical applications of cell therapy require further development and time.
Major concerns
Stem cell-based therapies must reach several milestones to overcome several critical issues before complete clinical application.
Cell sourcing
For cell replacement therapy, several critical issues concerning the cell source, including the cell quality, cell type and injected cell Z.-B. Jin, et al. Progress in Retinal and Eye Research 69 (2019) 38-56 number, need to be taken into full consideration. The quality of injected cells is a key element for the efficacy of cell survival and for safety. Variable protocols have been used in different laboratories at different facilities. Thus, when evaluating the different outcomes of separate clinical trials, the variability among cell sources should be considered. In addition, worldwide clinical trials using hESC-RPE, iPSC-RPE, BMSCs and CNS-SCs to protect neural retinal cells in RP, AMD and Stargardt's disease are currently underway. For stem cell-derived RPE cells, injected cells can integrate into endogenous RPE and replenish degenerated RPE. Moreover, BMSCs and CNS-SCs can secrete growth factors and modulate the microenvironment of the degenerating retina. Both strategies are applicable for clinical practice, and the quality of the cells is the key element. For clinical application, we have optimized a method for generation of the monolayer RPE without any artificial scaffolds and with a focus on quality, quantity, consistency, and safety. The gene expression patterns of iPSC-RPE are similar to those of native RPE and possess biological functions, such as the formation of tight junctions, polarized secretion of growth factors and phagocytotic ability . Relative to RPE differentiation, BMSC or CNS-SC isolation procedures are much easier, and these cells can be expanded rapidly in a relatively short period of time. However, we consider iPSC-RPE a competent source based on the varying rescue effects of iPSC-RPE, BMSCs and CNS-SCs on photoreceptor degeneration in rd1 mice (Sun et al., 2015) . There is no standardized number and volume for cell injection into the retina. Current clinical trials have injected 1.68 × 10 4 to 3.4 × 10 6 cells in a 100-150 μl suspension (Table 1) . Although a large number of preclinical studies have been conducted, the exact amount of cells needed for efficient transplantation in humans remains unclear.
In contrast to the case of the mouse model, human central vision is mainly dependent on cone photoreceptors, specifically the central rodfree region, the macular central fovea. Understanding the molecular basis of macular differentiation and synaptogenesis (Hoshino et al., 2017; Hendrickson and Zhang, 2017) is critical for the regeneration of the macula in human. It is thus urgently needed to develop a best-fitting method to generate cone-rich cells. Kruczek et al. (2017) established a modified protocol to increase cone differentiation in mouse ESCderived 3D retinal organoids by regulating the Notch pathway. However, it remains a problem to obtain cone photoreceptors of sufficient purity and fidelity differentiated from pluripotent stem cells.
Safety issue
Thus far, in the completed clinical trials, no tumor formation has been reported. However, the tumorigenicity of stem cell-derived cells remains the most concerning issue for cell transplantation. We have reviewed the design of tumorigenicity tests for iPSC-derived cell products . Additionally, the elimination of undifferentiated cells before transplantation can minimize the possibility of tumor formation (Kuroda et al., 2012) . Athymic nude rats have been used for tumorigenicity tests of iPSC-derived RPE sheets and hESC-RPE sheets/suspensions, and no signs of hyperproliferation, teratoma or tumor formation have been observed (Kanemura et al., 2014; Kawamata et al., 2015) . The advantageous natural structure of the eye makes it straightforward to detect abnormal proliferation, and it is unlikely that transplanted cells can escape from the eye and form tumors elsewhere because of the blood-retinal barrier.
Found as a cell monolayer underneath photoreceptor cells that possesses polarized secretion factors, RPE cells survive better when they are transplanted as a cell sheet rather than a cell suspension (Tezel and Del Priore, 1997) . However, during transplant surgery, it is challenging to maintain the RPE cell sheet in one piece and simultaneously avoid overlap of the tissue. Thus, skilled surgical technology is needed to minimize possible complications, and a suitable surgical device is needed to properly accomplish sheet transplantation. Retinal detachment is inevitable after transplantation of an RPE sheet or suspension, but a proper surgical device and procedure could certainly assist in retina recovery and reduce mechanical injury .
Immunogenicity concern
Immune rejection is a key problem for cell/tissue transplantation. From this perspective, autologous iPSC-derived cells are the ideal choice. Clinical trials using autologous iPSC-RPE cells have demonstrated no signs of immune rejection in the absence of immunosuppressive agents (Mandai et al., 2017b ). However, it seems The white asterisk indicates the underlying choroid vessels, which are visible after removal of the neovascular membrane. The yellow arrow indicates hemorrhages observed at the graft insertion site 3 days after surgery but were absorbed in 2 weeks. (C) The white arrow indicates the graft sheet that initially curled at its edge but flattened by 8 weeks. (D) The implant RPE sheet remained intact after 1 year. (Adapted from Kinoshita et al., 2016; Mandai et al., 2017b) . impossible to develop personalized RPE cells due to the high cost and time required for the generation of iPSC and RPE cell differentiation using clinical good manufacturing practices (GMP). In addition, considering the genetic background, allogeneic transplantation may be a better choice than autologous transplantation. The immune rejection reaction can be divided into innate and adaptive responses. During transplantation surgery, the innate immune system, including complement factors, natural killer cells and dendritic cells, can be activated by microbial products contained in the implanted cells or endogenous proinflammatory factors released with mechanical damage.
However, the survival rate of implanted cells is determined mainly by histocompatibility antigens, including MHC antigens, minor histocompatibility complex antigens and ABO antigens. MHC-I antigens are universally expressed in all nucleated cells, and MHC-II antigens are naturally restricted to certain cell types or circumstances (Zhang and Bok, 1998) . In RPE cells, MHC-I antigens are constitutively expressed, and MHC-II can be expressed upon stimulation of proinflammatory cytokines (Casella et al., 1999; Zhang and Bok, 1998) . MHC antigens can be recognized by a recipient's T cells, and the T cells subsequently promote the immune response (Lechler et al., 2005) . During organ transplantation, the survival rate significantly improves with MHC or HLA matching in humans. In vitro models have demonstrated the lack of T-cell responses to iPSC-derived RPE cells from HLA homozygous donors (Sugita et al., 2016b) . However, low levels of RPE cell survival were found and might be due to the activation of resident microglia (Xian and Huang, 2015) . Autologous or MHC-matched donor cells caused a weak immune response and exhibited improved neural cell grafting in the brain (Morizane et al., 2017) . Moreover, MHC-mismatched transplantation caused immune attacks against iPSC-RPE allografts that were prevented by MHC-matched transplantation (Sugita et al., 2016a) .
The subretinal space possesses immune-privilege characteristics, which seem to rely on the integrity of the RPE cell monolayer (Wenkel and Streilein, 1998) . RPE cells play an important role in maintaining the subretinal immunosuppressive status by secreting cytokines and growth factors (Sugita, 2009; Sugita et al., 2006 Sugita et al., , 2008 Sugita et al., , 2010 . TGF-β and thrombospondin released by RPE cells can suppress the adaptive immune response (Zamiri et al., 2005) , while production of the growth factor PEDF leads to the regulation of macrophage activation (Zamiri et al., 2006) . Immunosuppression can be affected by the maturation of RPE cells. The production of growth factors and cytokines is also determined by the polarization of these cells (Sonoda et al., 2010) . In our in vitro study, the iPSC-derived RPE cell sheet had the potential to inhibit T-cell activation (Sun et al., 2015) . The differences in immunosuppression between RPE cell suspensions and cell sheets may affect the long-term survival of these cells after transplantation. Alloreactive antibodies have been thoroughly investigated in the serum of a monkey model to determine the immune response after RPE transplantation. B-cell invasion and alloantibody-mediated immune attacks occurred in response to allogeneic iPS-RPE cells after transplantation in MHC haplotype-mismatched monkey eyes. Based on this study, we established a protocol for the detection of RPE-cell-specific antibodies using the recipient's serum (Sugita et al., 2017) .
Enhancing efficacy
All the current clinical trials are in Phase I/II. Safety testing is the first step of a clinical trial, and the final goal is efficacy improvement. Diniz et al. suggested that, relative to cell suspensions, polarized monolayers of hESC-RPE sheets show improved survival (Diniz et al., 2013) . A previous clinical trial revealed that autologous iPSC-RPE sheets remained intact at 1 year after transplantation (Mandai et al., 2017b) . However, improvement in visual acuity showed no correlation with the RPE survival rate (Schwartz et al., 2015) , which may be due to the interventional timing. The best time for RPE transplantation is after the start of RPE cell degeneration but when the photoreceptor cells are still alive. Once photoreceptor loss occurs, RPE cell replacement can no longer rescue vision. Under this circumstance, co-transplantation of RPE cells and photoreceptors may enhance efficacy. Otherwise, RPC replacement can be used to regenerate different retinal cell types, including photoreceptors. Retinal pigment epithelial stem cells (RPESCs) are a subpopulation of adult human RPE cells that can self-renew and produce differentiated progeny (Salero et al., 2012) . Transplantation of the progeny can preserve vision in RCS rats, and the efficacy for vision rescue is highly affected by the developmental stage of RPESC-derived RPE cells (Davis et al., 2017) . However, the application of these cells is limited by the availability of donor eyes. BMSCs can regulate the immune response and play roles in homeostasis, but how they influence vision is unclear (Kimbrel et al., 2014) . Similarly, co-injection of BMSCs and RPE cells may improve RPE cell survival. Moreover, the combination of RPE cells and neuroprotective factors might be beneficial.
Effective cost-down
Several companies have noticed the potential of cell therapy for treating retinal degeneration and participated in clinical trials. The cost of preclinical and clinical studies is high, and the burden of cost can fall to individual patients. Using autologous iPSC-RPE can avoid ethical issues associated with hESCs, and these cells have little risk of immune rejection. However, generation and identification of iPSC and RPE differentiation are time consuming and cost a substantial amount of money. Aiming for regenerative medicine, several institutes are collaborating to build a network of GMP HLA homozygous haplobanks (Turner et al., 2013) (Fig. 2) . By the end of 2022, the collection of the iPSC stock will be able to cover most of the Japanese population (CiRA, Center for iPS Cell Research and Application, Kyoto University) (https://www.cira.kyoto-u.ac.jp/e/research/stock.html). The cells can be used for medical care in treating retinal degeneration, Alzheimer's disease and leukemia, among other diseases. Thus, the cost for individual patients can markedly decrease.
Future directions
Owing to the extensive clinical and genetic heterogeneity of retinal degenerative diseases and the poor understanding of the common signaling pathways causing retinal cell death, it is challenging to design drugs to intervene in retinal degenerative diseases. Cell-based therapy is an alternative universal approach to target multiple diverse retinal degenerative diseases. Theoretically, replacing RPE cells may rescue visual function only in patients with remaining photoreceptor cells. For patients with advanced retinal degenerative diseases, visual improvement cannot be achieved even if the transplanted RPE cells are intact (Mandai et al., 2017b) . Several attempts have been made to transplant full-thickness retinal sheet in animal models (Aramant and Seiler, 2002; Ghosh et al., 1999 Ghosh et al., , 2004 Seiler et al., 2008) . The major concern preventing the further development of this method is the limited supply of retinal tissue.
Fortunately, the development of methods for 3D retinal tissue differentiation has provided new insights into retinal tissue transplantation. We have made several attempts to transplant stem cell-derived retinal tissue in mouse, rat and primate retinal degeneration models. Although the transplanted retinas formed rosettes in the subretinal space, considerable numbers of photoreceptors expressing rhodopsin or cone opsin with mature structures, such as IS/OS, were observed (Shirai et al., 2016) . Using double fluorescence-labeled animal models and implanted cells, direct contact between host bipolar cells and the synaptic terminals of graft rod photoreceptors were also observed (Mandai et al., 2017a) . Although material transfer might play a role in visual rescue after transplantation, the IS/OS structure and light-responsive RGCs observed in end-stage mouse models indicated that transplanted retinal sheets can mature and integrate into the host retina (Iraha et al., 2018) . These studies provide proof-of-concept evidence for the transplantation of stem cell-derived retinal tissue to treat retinal degenerative diseases.
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Conclusions
Stem cell science has opened an avenue to replace with and replenish induced retinal cells in diverse retinal degenerative diseases. Pluripotent stem cell-derived non-neuronal retinal pigment epithelial cells have been the first touchstone and successfully translated in human clinical trials, whereas there are challenging issues to be overcome. Beyond all doubt, neuro-retinal regeneration will be the next milestone changing the clinical management and outcome when research community fully harnesses the power of pluripotent stem cells.
